Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 27-32 , January 2010

The effect of mosapride citrate on constipation in patients with diabetes

  • Naohiko Ueno

      Affiliations

    • Department of Internal Medicine, Kobe Seaside Hospital, Japan
    • Corresponding Author InformationCorresponding author at: 1-1-28 Isobe-dori Chuo-ku Kobe, Hyogo 651-0084, Japan. Tel.: +81 78 251 8866; fax: +81 78 251 8866.
    • ,
  • Akio Inui

      Affiliations

    • Department of Psychosomatic Internal Medicine, Kagoshima University Graduate, School of Medical and Dental Sciences, Japan
    • ,
  • Yoshiko Satoh

      Affiliations

    • Department of Internal Medicine, Kobe Seaside Hospital, Japan

Received 29 October 2008 ,Revised 29 July 2009 ,Accepted 28 September 2009.

References 

  1. Goyal RK, Spiro HM. Gastrointestinal manifestations of diabetes mellitus. Med. Clin. North Am. 1971;55:1031–1044
  2. Keshavarzian A, Iber FL. Intestinal transit in insulin-requiring diabetics. Am. J. Gastroenterol. 1986;81:257–260
  3. Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann. Intern. Med. 1983;98:378–384
  4. Brown CK, Khanderia U. Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesis. Clin. Pharm. 1990;9:357–365
  5. Frazee LA, Mauro LS. Erythromycin in the treatment of diabetic gastroparesis. Am. J. Ther. 1994;1:287–295
  6. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs. 1982;24:360–400
  7. Kii Y, Nakatsuji K, Nose I, Yabuuchi M, Mizuki Y, Ito T. Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats. Pharmacol. Toxicol. 2001;89:96–103
  8. Gershon MD. Review article: serotonin receptors and transporters—roles in normal and abnormal gastrointestinal motility. Aliment. Pharmacol. Ther. Suppl. 2004;7:3–14
  9. Baxter GS, Craig DA, Clarke DE. 5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn Schmiedebergs Arch. Pharmacol. 1991;343:439–446
  10. Mader R, Kocher T, Haier J, Wieczorek G, Pfannkuche HJ, Ito M. Investigation of serotonin type 4 receptor expression in human and non-human primate gastrointestinal samples. Eur. J. Gastroenterol. Hepatol. 2006;18:945–950
  11. Ruth M, Finizia C, Cange L, Lundell L. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 2003;15:1115–1121
  12. Mizuta Y, Shikuwa S, Isomoto H, Mishima R, Akazawa Y, Masuda J, et al. Recent insights into digestive motility in functional dyspepsia. J. Gastroenterol. 2006;41:1025–1040
  13. Yoshida N, Omoya H, Oka M, Furukawa K, Ito T, Karasawa T. AS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties. Arch. Int. Pharmacodyn. Ther. 1989;300:51–67
  14. Asakawa H, Hayashi I, Fukui T, Tokunaga K. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res. Clin. Pract. 2003;61:175–182
  15. Talley NJ. Serotoninergic neuroenteric modulators. Lancet. 2001;358:2061–2068
  16. Liu Z, Sakakibara R, Odaka T. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients. Mov. Disord. 2005;20:680–686
  17. Ueno N, Inui A, Asakawa A, Takao F, Komatsu Y, Kotani KA, et al. Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with Type II diabetes mellitus. Diabetologia. 2002;45:792–797
  18. McLean PG, Coupar IM. Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5-HT4-like receptors. Br. J. Pharmacol. 1996;117:238–239
  19. Sakurai-Yamashita Y, Yamashita K, Yoshimura M, Taniyama K. Differential localization of 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptors in the human rectum. Life Sci. 2000;66:31–34
  20. Longo WE, Vernava AM. Prokinetic agents for lower gastrointestinal motility disorders. Dis. Colon Rectum. 1993;36:696–708
  21. Svedlund J, Sjödin I, Dotevall G. GSRS—a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. 1988;33:129–134
  22. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual. Life Res. 1998;7:75–83
  23. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006;29:1538–1544
  24. Pietraszek MH, Takada Y, Takada A, Fujita M, Watanabe I, Taminato A, et al. Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. Thromb. Res. 1992;66:765–774
  25. Spångéus A, Kand M, El-Salhy M. Gastrointestinal endocrine cells in an animal model for human type 2 diabetes. Dig. Dis. Sci. 1999;44:979–985
  26. Inui A, Yoshikawa T, Nagai R, Yoshida N, Ito T. A 5-HT4 receptor agonist, on colonic motility inconscious guinea pig. Jpn. J. Pharmacol. 2002;90:313–320
  27. Kadowaki M, Wang XO, Shimatani H, Yoneda S, Takaki M. 5-HT4 receptor enhances the propulsive power of the peristaltic reflex in the rat distal colon. Auton. Neurosci. 2002;99:62–65
  28. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Characterization of swallowing and defecation in Parkinson's disease. Am. J. Gastroenterol. 1994;89:15–25
  29. Odaka T, Suzuki T, Seza A, Yamaguchi T, Saisho H. Serotonin 5-HT4 receptor agonist (mosapride citrate). Nippon Rinsho. 2006;64:1491–1494
  30. Shimatani H, Kojima Y, Kadowaki M, Nakagawa T, Fujii H, Nakajima Y, et al. A 5-HT4 agonist mosapride enhances rectorectal and rectoanal reflexes in guinea pigs. Am. J. Physiol. Gastrointest. Liver Physiol. 2003;285:G389–395
  31. Iida M, Ikeda M, Kishimoto M, Tsujino T, Kaneto H, Matsuhisa M, et al. Evaluation of gut motility in type II diabetes by the radiopaque marker method. J. Gastroenterol. Hepatol. 2000;15:381–385
  32. Werth B, Meyer-Wyss B, Spinas GA, Drewe J, Beglinger C. Non-invasive assessment of gastrointestinal motility disorders in diabetic patients with and without cardiovascular signs of autonomic neuropathy. Gut. 1992;33:1199–1203
  33. Battle WM, Snape WJ, Alavi A. Colonic dysfunction in diabetes mellitus. Gastroenterology. 1980;79:1217–1221
  34. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397–414
  35. Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev. Gastroenterol. Disord. 2003;(Suppl 2):S25–34
  36. Poole DP, Xu B, Koh SL, Hunne B, Coupar IM, Irving HR, et al. Identification of neurons that express 5-hydroxytryptamine4 receptors in intestine. Cell Tissue Res. 2006;325:413–442
  37. Taniyama K, Makimoto N, Furuichi A, Sakurai-Yamashita Y, Nagase Y, Kaibara M, et al. Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxytryptamine4 receptor, in gastrointestinal motility. J. Gastroenterol. 2000;35:575–582

PII: S0168-8227(09)00416-1

doi: 10.1016/j.diabres.2009.09.024

Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 27-32 , January 2010

Article Tools

* Image Usage & Resolution